addiction-science-dementia-care-2019-scientifictracks

4 / 9

Page 21
Volume 2
DEMENTIA AND DEMENTIA CARE
ADVANCES IN ADDICTION SCIENCE AND MEDICINE
July 24-25, 2019 | Rome, Italy
10th International Conference on
2nd World Congress on
&
Addiction Science 2019 & Dementia Care 2019
July 24-25, 2019
Journal of Clinical Psychiatry and Neuroscience
J Clin Psychiatr Neurosci, Volume 2
Safety of plasmaAβ1-42 andAβ1-40 reduction withH.E.A.L.E.R. (Haemoadsorption for
Extracorporeal Amyloid-β Level Expedited Reduction) using BETACLEAR BICARB
1000 in healthy elderly individuals
Miguel A Ramos Jr
St. Luke’s Medical Center, Philippines
Alzheimer’s disease (AD) is a growing concern
worldwide due to rise in the elderly population.
Symptomatic agents remain to be the cornerstone in its
management, whereas the pathological cortical changes
are amyloid β-protein plaques and neurofibrillary tangles.
Despite well-defined changes in the brain that deleteriously
lead to the myriad of symptoms of AD, the Amyloid
hypothesis maintains its stronghold in the causation of AD.
This study aims to evaluate the safety of H.E.A.L.E.R.
procedure with the Amylex BETACLEAR BICARB 1000
in healthy elderly individuals. This product contains a
nanomolecular peptide in a sodium bicarbonate compound
used as component of dialysate in conjunction with high-
flux membrane dialyzer configuration for a hemodialysis
procedure in bypass mode. Its active agent specifically
targets β-amyloids and facilitates their extraction from the
blood. The result is a reduction in the levels of β-amyloids (Aβ1-40 andAβ1-42) in the patient’s body. Patient information booklet
and informed consent will be administered to 3 participants, who will undergo complete physical, neurological and cognitive
examination, alongside medical history and drug review. Laboratory and ancillary tests will be done, and patients will undergo
cardiac clearance prior. Once qualified, they will be admitted at St. Luke’s Medical Center (SLMC) at pre-defined conditions.
A triple lumen venous catheter will be inserted percutaneously at the internal jugular vein to be used for the extracorporeal
procedure. Lumbar tap will be performed twice to determine the β-amyloids level in the CSF. Plasma β-amyloids will be done
immediately before and after each procedure. ELISA technique will be used for Plasma and CSF β-amyloids level determination.
Safety monitoring of patients will be in place. After about 25 days, the patients will be discharged once they are deemed fit and
free of adverse effects. They will be reexamined after a month. Ethics Committee approval has been obtained and maintained.
Biography
Miguel A Ramos Jr. is a well-known medical professional and clinical researcher in the field of geriatrics. He is currently the Medical
Director of the National Center for Geriatric Health and president of the Philippine Society of Geriatric Medicine. He is also the Director
of the Geriatrics Center at St. Luke’s Medical Center and is set to be the Head of the new Geriatrics Department in the National
Kidney and Transplant Institute. He has extensive experience in the field of age-related diseases and is a founding member of several
Alzheimer’s organizations such as Dementia Society of the Philippines and Alzheimer’s Disease Association of the Philippines.